Summary
The effects were measured and compared of three nonselective cysteine cathepsin inhibitors (leupeptin, trans-Epoxysuccinyl-l-Leucylamido(4-guanidino)-butane (E-64), and Z-Phe-Ala-CH2F) and a selective cathepsin B inhibitor, CA074Me, on the intracellular processing of 125I-labeled human recombinant Interleukin 6 (IL-6) by HepG2 cells. The uptake and processing of 125I-IL-6 by cells treated with inhibitors was followed over a 7-h period. All inhibitors caused an increased residence time of IL-6 inside the cell and a corresponding decrease in the output of non-trichloroacetic acid-precipitable fragments of radiolabeled protein. Maximal effect was achieved with leupeptin at 200 µM, with which the rate of IL-6 digestion was reduced to 50% that of control cells. The specific inhibitor CA074Me was the least effective in slowing the intracellular processing of IL-6. The effects of all of the inhibitors on the production of haptoglobin, either stimulated by IL-6 or basal, was negligible over a similar time period, indicating continued cell viability. The data from this model suggest that cathepsin inhibitors would not interfere with lysosomal processing to an extent which would prohibit the development of selective and potent cathepsin inhibitors for the treatment of diseases in which individual cysteine cathepsins play clearly pathophysiological roles.
Similar content being viewed by others
References
Bohley, P.; Seglen, P. Proteases and proteolysis in the lysosome. Experientia 48:151–157; 1992.
Buttle, D. J.; Murata, M.; Knight, C. G., et al. CA074 Methyl ester: a proinhibitor for intracellular cathepsin B. Arch. Biochem. Biophys. 299:377–380; 1992.
Elliott, E.; Sloane, B. F. The cysteine protease cathepsin B in cancer. Perspect. Drug Discov. Des. 6:12–32; 1996.
Gabrijelcic, D.; Annan-Prah, A.; Rodic, B., et al. Determination of cathepsin B and H in sera and synovial fluids of patients with different joint diseases. J. Clin. Chem. Biochem. 28:149–153; 1990.
Gauldie, J.; Richards, C.; Harnish, D.; Landsdorp, P.; Baumann, H. Interferon beta 2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84:7251–7255; 1987.
Gearing, D.; Comeau, M.; Friend, D., et al. The IL-6 signal transducer, gp130: an Oncostatin M receptor and affinity converter for the LIF receptor. Science (Wash DC) 255:1434–1437; 1992.
Gerhartz, C.; Dittrich, E.; Stoyan, T., et al. Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur. J Biochem. 223:265–274; 1994.
Grinde, B. Selective inhibition of lysosomal protein degradation by the thiol proteinase inhibitors E-64, Ep-459 and Ep-475 in isolated rat hepatocytes. Biochim. Biophys. Acta 701:328–332; 1992.
Mach, L.; Mort, J. S.; Glossl, J. Maturation of human procathepsin B. J. Biol. Chem. 269:13030–13040; 1994.
Matsunaga, Y.; Saibara, H.; Kido, H., et al. Participation of cathepsin B in processing of antigen presentation to MHC class II. FEBS Lett. 324:325–328; 1993.
Morton, P.; Zacheis, M.; Giacoletto, K., et al. Delivery of nascent MHC Class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J. Immunol. 154:137–150; 1995.
Muller-Ladner, U.; Gay, R.; Gay, S. Cysteine proteinases in arthritis and inflammation. Perspect. Drug Discov. Des. 6:87–98; 1996.
Nesbitt, J. E.; Fuller, G. Dynamics of interleukin-6 internalization and degradation in rat hepatocytes. J. Biol. Chem. 267:5739–5748; 1992.
Ohshita, T.; Nikawa, T.; Towattari, T., et al. Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro. Eur. J. Biochem. 209:223–231; 1992.
Peppard, J. V.; Smith, H. D.; Zhou, S. Kinetics of a cellular response to Interleukin 6. Cell. Immunol. 155:253–258; 1994.
Riese, R. J.; Wolf, P. A.; Bromme, D., et al. Essential role for cathepsin S in MHC Class II-associated invariant chain processing and peptide loading. Immunity 4:357–363; 1996.
Rodriguez, G.; Diment, S. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin. Eur. J. Immunol. 25:182–187; 1995.
Spizz, G.; Blackshear, P. J. Identification and characterization of cathepsin B as the cellular MARCKS cleaving enzyme. J. Biol. Chem. 272:23833–23842; 1997.
Steed, P. M.; Lasala, D.; Liebman, J., et al. Characterization of recombinant human cathepsin B expressed at high levels in baculovirus. Protein Sci. 7:2033–2037; 1998.
Taga, T.; Kishimoto, T. Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr. Opin. Immunol. 7:17–23; 1995
Xu, M.; Capraro, G.; Daibata, M., et al. Cathepsin B cleavage and release of invariant chain from MHC Class II molecules follow a staged pattern. Mol. Immunol. 31:723–731; 1994.
Zolnhoefer, D.; Graeve, L.; Rose-John, S., et al. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp180) by its ligand. FEBS Lett. 306:219–222; 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peppard, J.V., Knap, A.K. Effect of selective and non-selective cysteine protease inhibitors on the intracellular processing of interleukin 6 by HepG2 cells. In Vitro Cell.Dev.Biol.-Animal 35, 459–464 (1999). https://doi.org/10.1007/s11626-999-0052-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11626-999-0052-2